Opinion
MDL 2445 13-MD-2445
02-02-2022
IN RE SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION v. Indivior Inc. et al. THIS DOCUMENT RELATES TO, Wisconsin, et al. STATE OF WISCONSIN By Attorney General Brad D. Schimel, et al. Plaintiffs, v. INDIVIOR INC. f/k/a RECKITT BENCKISER PHARMACEUTICALS, INC., et al. Defendants. CIV. A. No. 16-5073
MITCHELL S. GOLDBERG, J.
ORDER
MITCHELL S. GOLDBERG, J.
AND NOW this 2nd day of February, 2022, upon consideration of Defendant Indivior, Inc.'s Renewed Motion to Disqualify Rochester Drug Co-Operative and Its Counsel from Representing the Direct Purchaser Class (Doc. No. 735), the Direct Purchaser Plaintiffs' Response (Doc. No. 737), the Direct Purchaser Plaintiffs' Notice of Supplemental Authority (Doc. No. 767), and Defendant Indivior, Inc.'s Response to the Notice of Supplemental Authority (Doc. No. 768), it is hereby ORDERED that the Motion is DENIED.